Circulating levels of inflammation-associated mir-155 and endothelial-enriched mir-126 in patients with end-stage renal disease

Brazilian Journal of Medical and Biological Research

Volumn 45, Issue 12, 2012, Pages 1308-1314

  Wang, Honglei ^a   Peng, Wujian ^a   Shen, Xuemei ^a   Huang, Yunhui ^a   Ouyang, Xin ^a   Dai, Yong ^a  

^a JINAN UNIVERSITY   (China)

Author keywords

End stage renal disease; Hemodialysis; MicroRNAs; Mir 126; Mir 155

Indexed keywords

ALBUMIN; C REACTIVE PROTEIN; CALCIUM; HEMOGLOBIN; MICRORNA 126; MICRORNA 155; PHOSPHATE;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; ENDOTHELIUM; FEMALE; GLOMERULUS FILTRATION RATE; HOMEOSTASIS; HUMAN; INFLAMMATION; KIDNEY FAILURE; MALE; REAL TIME POLYMERASE CHAIN REACTION; RISK ASSESSMENT; RISK FACTOR; RNA ISOLATION;

BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; FEMALE; HUMANS; KIDNEY FAILURE, CHRONIC; MALE; MICRORNAS; MIDDLE AGED; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

EID: 84872319199     PISSN: 0100879X     EISSN: 1414431X     Source Type: Journal    
DOI: 10.1590/S0100-879X2012007500165     Document Type: Article

References (29)

1. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 2004; 116: 281-297.
2. Zhang Q, Kandic I, Kutryk MJ. Dysregulation of angiogen- esis-related microRNAs in endothelial progenitor cells from patients with coronary artery disease. Biochem Biophys Res Commun 2011; 405: 42-46.
3. Zhu N, Zhang D, Chen S, Liu X, Lin L, Huang X, et al. Endothelial enriched microRNAs regulate angiotensin II- induced endothelial infammation and migration. Atheroscle- rosis 2011; 215: 286-293.
4. Sequeira Lopez ML, Gomez RA. Novel mechanisms for the control of renin synthesis and release. Curr Hypertens Rep 2010; 12: 26-32.
5. Amrouche L, Bonifay R, Anglicheau D. MicroRNAs in pathophysiology of renal disease: an increasing interest. Med Sci 2011; 27: 398-404.
6. Shi S, Yu L, Chiu C, Sun Y, Chen J, Khitrov G, et al. Podo- cyte-selective deletion of dicer induces proteinuria and glom- erulosclerosis. J Am Soc Nephrol 2008; 19: 2159-2169.
7. Dai Y, Sui W, Lan H, Yan Q, Huang H, Huang Y. Compre- hensive analysis of microRNA expression patterns in renal biopsies of lupus nephritis patients. Rheumatol Int 2009; 29: 749-754.
8. Levin A. Clinical epidemiology of cardiovascular disease in chronic kidney disease prior to dialysis. Semin Dial 2003; 16: 101-105.
9. Stinghen AE, Pecoits-Filho R. Vascular damage in kidney disease: beyond hypertension. Int J Hypertens 2011; 2011: 232683.
10. Stenvinkel P, Carrero JJ, Axelsson J, Lindholm B, Heim- burger O, Massy Z. Emerging biomarkers for evaluating cardiovascular risk in the chronic kidney disease patient: how do new pieces ft into the uremic puzzle? Clin J Am Soc Nephrol 2008; 3: 505-521.
11. Zampetaki A, Kiechl S, Drozdov I, Willeit P, Mayr U, Prokopi M, et al. Plasma microRNA profling reveals loss of endothe- lial miR-126 and other microRNAs in type 2 diabetes. Circ Res 2010; 107: 810-817.
12. Mitchell PS, Parkin RK, Kroh EM, Fritz BR, Wyman SK, Pogosova-Agadjanyan EL, et al. Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci U S A 2008; 105: 10513-10518.
13. Cortez MA, Calin GA. MicroRNA identifcation in plasma and serum: a new tool to diagnose and monitor diseases. Expert Opin Biol Ther 2009; 9: 703-711.
14. Arroyo JD, Chevillet JR, Kroh EM, Ruf IK, Pritchard CC, Gibson DF, et al. Argonaute2 complexes carry a population of circulating microRNAs independent of vesicles in human plasma. Proc Natl Acad Sci U S A 2011; 108: 5003-5008.
15. Fichtlscherer S, de Rosa S, Fox H, Schwietz T, Fischer A, Liebetrau C, et al. Circulating microRNAs in patients with coronary artery disease. Circ Res 2010; 107: 677-684.
16. Ai J, Zhang R, Li Y, Pu J, Lu Y, Jiao J, et al. Circulating mi- croRNA-1 as a potential novel biomarker for acute myocar- dial infarction. Biochem Biophys Res Commun 2010; 391: 73-77.
17. Livak KJ, Schmittgen TD. Analysis of relative gene expres- sion data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 2001; 25: 402-408.
18. Dursun I, Poyrazoglu HM, Gunduz Z, Ulger H, Yykylmaz A, Dusunsel R, et al. The relationship between circulating endothelial microparticles and arterial stiffness and athero- sclerosis in children with chronic kidney disease. Nephrol Dial Transplant 2009; 24: 2511-2518.
19. Yao Q, Lindholm B, Stenvinkel P. Infammation as a cause of malnutrition, atherosclerotic cardiovascular disease, and poor outcome in hemodialysis patients. Hemodial Int 2004; 8: 118-129.
20. Fish JE, Santoro MM, Morton SU, Yu S, Yeh RF, Wythe JD, et al. miR-126 regulates angiogenic signaling and vascular integrity. Dev Cell 2008; 15: 272-284.
21. Wang S, Aurora AB, Johnson BA, Qi X, McAnally J, Hill JA, et al. The endothelial-specifc microRNA miR-126 governs vascular integrity and angiogenesis. Dev Cell 2008; 15: 261-271.
22. Staszel T, Zapala B, Polus A, Sadakierska-Chudy A, Kiec- Wilk B, Stepien E, et al. Role of microRNAs in endothelial cell pathophysiology. Pol Arch Med Wewn 2011; 121: 361-366.
23. Martin MM, Buckenberger JA, Jiang J, Malana GE, Nuovo GJ, Chotani M, et al. The human angiotensin II type 1 re- ceptor +1166 A/C polymorphism attenuates microRNA-155 binding. J Biol Chem 2007; 282: 24262-24269.
24. Martin MM, Lee EJ, Buckenberger JA, Schmittgen TD, Elton TS. MicroRNA-155 regulates human angiotensin II type 1 receptor expression in fbroblasts. J Biol Chem 2006; 281: 18277-18284.
25. Zernecke A, Bidzhekov K, Noels H, Shagdarsuren E, Gan L, Denecke B, et al. Delivery of microRNA-126 by apoptotic bodies induces CXCL12-dependent vascular protection. Sci Signal 2009; 2: 81.
26. Neal CS, Michael MZ, Pimlott LK, Yong TY, Li JY, Gleadle JM. Circulating microRNA expression is reduced in chronic kidney disease. Nephrol Dial Transplant 2011; 26: 3794-3802.
27. Amabile N, Guerin AP, Tedgui A, Boulanger CM, London GM. Predictive value of circulating endothelial microparticles for cardiovascular mortality in end-stage renal failure: a pilot study. Nephrol Dial Transplant 2012; 27: 1873-1880.
28. Tesse A, Martinez MC, Meziani F, Hugel B, Panaro MA, Mitolo V, et al. Origin and biological significance of shed- membrane microparticles. Endocr Metab Immune Disord Drug Targets 2006; 6: 287-294.
29. Prokopi M, Pula G, Mayr U, Devue C, Gallagher J, Xiao Q, et al. Proteomic analysis reveals presence of platelet microparticles in endothelial progenitor cell cultures. Blood 2009; 114: 723-732.